Non Hodgkin Lymphoma Clinical Trial
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Summary
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
Eligibility Criteria
Inclusion Criteria:
Subjects must be currently receiving treatment with ublituximab and/or TGR-1202 on a previously approved protocol.
Subjects must have completed at least 6 cycles of therapy on their current protocol.
Exclusion Criteria:
Subject progressed while receiving therapy with ublituximab and/or TGR-1202 while participating in their immediate previous trial.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
Huntsville Alabama, 35805, United States
Tucson Arizona, 85711, United States
Fayetteville Arkansas, 72703, United States
Duarte California, 91010, United States
Fort Myers Florida, 33901, United States
Atlanta Georgia, 30322, United States
Fort Wayne Indiana, 46804, United States
Coon Rapids Minnesota, 55433, United States
Omaha Nebraska, 68198, United States
Durham North Carolina, 27710, United States
Canton Ohio, 44718, United States
Cincinnati Ohio, 45242, United States
Nashville Tennessee, 37203, United States
Denton Texas, 76210, United States
San Antonio Texas, 78229, United States
Seattle Washington, 98104, United States
Milwaukee Wisconsin, 53226, United States
How clear is this clinincal trial information?